Prostatic urethral lift for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 10, 2017, Pages

  Jung, Jae Hung ^a,b,c   Mccutcheon, Karen Ann ^d   Reddy, Balaji ^e   Borofsky, Michael ^b   Narayan, Vikram ^b   Kim, Myung Ha ^a   Dahm, Philipp ^b,c  

^a Yonsei University Wonju College of Medicine   (South Korea)

^b UNIVERSITY OF MINNESOTA   (United States)

^c VA MEDICAL CENTER   (United States)

^d QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DYSURIA; EVIDENCE BASED MEDICINE; HEMATURIA; HOLMIUM LASER ENUCLEATION OF THE PROSTATE; HUMAN; INTERMETHOD COMPARISON; INTERNATIONAL PROSTATE SYMPTOM SCORE; LENGTH OF STAY; LOWER URINARY TRACT SYMPTOM; MINIMALLY INVASIVE SURGERY; OUTCOME ASSESSMENT; PARALLEL DESIGN; PENIS ERECTION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROSTATE SURGERY; PROSTATE VOLUME; PROSTATECTOMY; PROSTATIC URETHRAL LIFT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REOPERATION; SYSTEMATIC REVIEW; TRANSURETHRAL RESECTION; URETHRA SURGERY; URINE INCONTINENCE; URINE RETENTION;

EID: 85032359214     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD012832     Document Type: Article

References (58)

1. Agarwal A, Eryuzlu LN, Cartwright R, Thorlund K, Tammela TL, Guyatt GH, et al. What is the most bothersome lower urinary tract symptom? Individual- and population-level perspectives for both men and women. European Urology 2014;65(6):1211-7.
2. Barry MJ, Fowler FJ Jr, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. Journal of Urology 1992;148(5):1549-57; discussion 1564.
3. Barry MJ, Williford WO, Chang Y, Machi M, Jones K, Walker-Corkery E, et al. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?. Journal of Urology 1995;154(5):1770-4.
4. Barry MJ, Fowler FJ Jr, Bin L, Pitts JC 3rd, Harris CJ, Mulley AG Jr. The natural history of patients with benign prostatic hyperplasia as diagnosed by North American urologists. Journal of Urology 1997;157(1):10-4; discussion 14-5.
5. Bhojani N, Gandaglia G, Sood A, Rai A, Pucheril D, Chang SL, et al. Morbidity and mortality after benign prostatic hyperplasia surgery: data from the American College of Surgeons national surgical quality improvement program. Journal of Endourology 2014;28(7):831-40.
6. Brasure M, MacDonald R, Dahm P, Olson CM, Nelson VA, Fink HA, et al. AHRQ comparative effectiveness reviews. Newer medications for lower urinary tract symptoms attributed to benign prostatic hyperplasia: a review. Rockville (MD): Agency for Healthcare Research and Quality (US), 2016.
7. Chapple C, Castro-Diaz D, Chuang YC, Lee KS, Liao L, Liu SP, et al. Prevalence of lower urinary tract symptoms in China, Taiwan, and South Korea: results from a cross-sectional, population-based study. Advances in Therapy 2017 Jul 7 [Epub ahead of print].
8. Chin PT, Bolton DM, Jack G, Rashid P, Thavaseelan J, Yu RJ, et al. Prostatic urethral lift: two-year results after treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology 2012;79(1):5-11.
9. Cornu JN, Cussenot O, Haab F, Lukacs B. A widespread population study of actual medical management of lower urinary tract symptoms related to benign prostatic hyperplasia across Europe and beyond official clinical guidelines. European Urology 2010;58(3):450-6.
10. Veritas Health Innovation. Covidence. Version accessed 16 August 2017. Melbourne, Australia: Veritas Health Innovation, 2013.
11. Crawford ED, Wilson SS, McConnell JD, Slawin KM, Lieber MC, Smith JA, et al. Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. Journal of Urology 2006;175(4):1422-6; discussion 1426-7.
12. Deeks JJ, Higgins JP, Altman DG, editor(s). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
13. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Annals of Surgery 2004;240(2):205-13.
14. Dunphy C, Laor L, Te A, Kaplan S, Chughtai B. Relationship between depression and lower urinary tract symptoms secondary to benign prostatic hyperplasia. Reviews in Urology 2015;17(2):51-7.
15. European Association of Urology. Treatment of non-neurogenic male LUTS. uroweb.org/guideline/treatment-of-non-neurogenic-male-luts/ (accessed 17 August 2017).
16. Egan KB. The epidemiology of benign prostatic hyperplasia associated with lower urinary tract symptoms: prevalence and incident rates. Urologic Clinics of North America 2016;43(3):289-97.
17. Clarivate Analytics. EndNote. Version 7.5. Clarivate Analytics, 2016.
18. McMaster University (developed by Evidence Prime). GRADEpro GDT. Version accessed 16 August 2017. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015.
19. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Schünemann HJ, et al. GRADE: what is "quality of evidence" and why is it important to clinicians?. BMJ (Clinical Research Ed) 2008;336(7651):995-8.
20. Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al. GRADE guidelines 6. Rating the quality of evidence - imprecision. Journal of Clinical Epidemiology 2011;64(12):1283-93.
21. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction - GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64(4):383-94.
22. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002;21(11):1539-58.
23. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ (Clinical Research Ed) 2003;327(7414):557-60.
24. Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
25. Higgins JP, Altman DG, Sterne JAC, editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
26. Higgins JP, Deeks JJ, Altman DG, editor(s). Chapter 16: Special topics in statistics. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
27. Homma Y, Kawabe K, Tsukamoto T, Yamanaka H, Okada K, Okajima E, et al. Epidemiologic survey of lower urinary tract symptoms in Asia and Australia using the international prostate symptom score. International Journal of Urology 1997;4(1):40-6.
28. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Controlled Clinical Trials 1989;10(4):407-15.
29. Johnston BC, Patrick DL, Busse JW, Schünemann HJ, Agarwal A, Guyatt GH. Patient-reported outcomes in meta-analyses - Part 1: assessing risk of bias and combining outcomes. Health and Quality of Life Outcomes 2013;11:109.
30. Jones P, Rajkumar GN, Rai BP, Aboumarzouk OM, Cleaveland P, Srirangam SJ, et al. Medium-term outcomes of UroLift (minimum 12 months follow-up): evidence from a systematic review. Urology 2016;97:20-4.
31. Kozminski MA, Wei JT, Nelson J, Kent DM. Baseline characteristics predict risk of progression and response to combined medical therapy for benign prostatic hyperplasia (BPH). BJU International 2015;115(2):308-16.
32. Leissner KH, Tisell LE. The weight of the human prostate. Scandinavian Journal of Urology 1979;13(2):137-42.
33. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Medicine 2009;6(7):e1000100.
34. Martin S, Lange K, Haren MT, Taylor AW, Wittert G. Risk factors for progression or improvement of lower urinary tract symptoms in a prospective cohort of men. Journal of Urology 2014;191(1):130-7.
35. McNicholas TA. Benign prostatic hyperplasia and new treatment options - a critical appraisal of the UroLift system. Medical Devices 2016;9:115-23.
36. McVary KT, Roehrborn CG, Avins AL, Barry MJ, Bruskewitz RC, Donnell RF, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. Journal of Urology 2011;185(5):1793-803.
37. National Institute for Health and Care Excellence. UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia. https://www.nice.org.uk/guidance/mtg26 (accessed 28 September 2017).
38. Nickel JC, Brock GB, Herschorn S, Dickson R, Henneges C, Viktrup L. Proportion of tadalafil-treated patients with clinically meaningful improvement in lower urinary tract symptoms associated with benign prostatic hyperplasia - integrated data from 1, 499 study participants. BJU International 2015;115(5):815-21.
39. Pariser JJ, Pearce SM, Patel SG, Bales GT. National trends of simple prostatectomy for benign prostatic hyperplasia with an analysis of risk factors for adverse perioperative outcomes. Urology 2015;86(4):721-5.
40. Perera M, Roberts MJ, Doi SA, Bolton D. Prostatic urethral lift improves urinary symptoms and flow while preserving sexual function for men with benign prostatic hyperplasia: a systematic review and meta-analysis. European Urology 2015;67(4):704-13.
41. Reeves BC, Deeks JJ, Higgins JP, Wells GA, editor(s). Chapter 13: Including non-randomized studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
42. Reich O, Gratzke C, Bachmann A, Seitz M, Schlenker B, Hermanek P, et al. Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10, 654 patients. Journal of Urology 2008;180(1):246-9.
43. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
44. Roehrborn C, McConnell J, Barry M, Benaim E, Bruskewitz R, Blute ML, et al. American Urological Association guideline: management of benign prostatic hyperplasia (BPH). www.auanet.org/documents/education/clinical-guidance/Benign-Prostatic-Hyperplasia.pdf (accessed 28 September 2017).
45. Roehrborn CG. Pathology of benign prostatic hyperplasia. International Journal of Impotence Research 2008;20 Suppl 3:S11-8.
46. Roehrborn CG. Current medical therapies for men with lower urinary tract symptoms and benign prostatic hyperplasia: achievements and limitations. Review in Urology 2008;10(1):14-25.
47. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997;49(6):822-30.
48. Rosen RC, Catania JA, Althof SE, Pollack LM, O'Leary M, Seftel AD, et al. Development and validation of four-item version of Male Sexual Health Questionnaire to assess ejaculatory dysfunction. Urology 2007;69(5):805-9.
49. Rosen RC, Allen KR, Ni X, Araujo AB. Minimal clinically important differences in the erectile function domain of the International Index of Erectile Function scale. European Urology 2011;60(5):1010-6.
50. Sanchez-Gomez LM, Polo-deSantos M, Gomez-Sancha F, Luengo-Matos S. Efficacy and safety of the urolift ® system for the treatment of benign prostate hyperplasia symptoms: systematic review. Actas Urológicas Españolas 2015;39(5):311-9.
51. Schunemann HJ, Tugwell P, Reeves BC, Akl EA, Santesso N, Spencer FA, et al. Non-randomized studies as a source of complementary, sequential or replacement evidence for randomized controlled trials in systematic reviews on the effects of interventions. Research Synthesis Methods 2013;4(1):49-62.
52. Schünemann HJ, Oxman AD, Higgins JP, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
53. Schünemann HJ, Oxman AD, Vist GE, Higgins JP, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
54. Spaliviero M, Strom KH, Gu X, Araki M, Culkin DJ, Wong C. Does Greenlight HPS (™) laser photoselective vaporization prostatectomy affect sexual function?. Journal of Endourology 2010;24(12):2051-7.
55. Sterne JA, Hernan MA, Reeves BC, Savovic J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016;355:i4919.
56. World Health Organization. Proposed working definition of an older person in Africa for the MDS project. www.who.int/healthinfo/survey/ageingdefnolder/en (accessed 17 August 2017).
57. Woo HH, Bolton DM, Laborde E, Jack G, Chin PT, Rashid P, et al. Preservation of sexual function with the prostatic urethral lift: a novel treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Journal of Sexual Medicine 2012;9(2):568-75.
58. Yoo TK, Cho HJ. Benign prostatic hyperplasia: from bench to clinic. Korean Journal of Urology 2012;53(3):139-48.